|
|
|
|
|
||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
|
Clanotech aims to deliver novel anti-angiogenic compounds, VEGFRs & Integrin inhibitors for the treatment of solid cancers and age related macular degeneration (AMD). |
|
  |
||||||||||
ClanoTech AB • Fogdevreten 2 • S-17165 Solna • Sweden • Org. nr. 556706-6658 • Registered office: Solna